SimBioSys and Ricoh Team Up to Enhance Breast Cancer Surgery with TumorSight Viz

Strategic Alliance to Transform Breast Cancer Surgery

In a groundbreaking announcement, SimBioSys®, a leading AI clinical company specializing in the field of breast cancer treatment, has partnered with Ricoh 3D for Healthcare. This strategic alliance aims to improve the accessibility of TumorSight™ Viz, an advanced surgical visualization platform. Recently granted FDA approval, TumorSight Viz helps surgeons in making more precise and informed decisions during breast cancer surgeries.

Enhanced Surgical Visualization

TumorSight™ Viz utilizes sophisticated technology to transform standard breast MRI scans into intuitive 3D visualizations. This innovative approach provides clear insights into tumor size, location, and orientation within the context of surrounding anatomy. Surgeons can access this valuable information rapidly, allowing for faster case planning and coordination, which are crucial in a clinical setting.

According to Stacey Stevens, President and CEO of SimBioSys, the partnership will significantly contribute towards meeting the increasing demand for precision tools in surgical oncology. The ultimate goal is to empower practitioners with more robust decision-making capabilities that enhance patient outcomes while reducing variability in surgical procedures.

Ricoh's Role in Expanding Access

As a subsidiary of Ricoh USA, Inc., Ricoh 3D for Healthcare brings essential expertise in healthcare services and an extensive network of relationships with surgical oncology clinicians. This collaboration aligns with Ricoh's mission to deliver personalized healthcare solutions that are both innovative and patient-specific, resulting in better surgical outcomes.

Derek Mathers, the Director of Clinical Applications at Ricoh, emphasized the importance of surgical strategies that not only effectively eliminate tumors but also enhance patients' quality of life. Through their partnership with SimBioSys, the TumorSight Viz platform is positioned to significantly improve surgical planning, thereby promoting techniques that enable breast-conserving options.

Robust Clinical Validation

The development of TumorSight Viz is supported by clinical studies showcasing its accuracy and reliability. The platform demonstrates a strong correlation with radiologist annotations, establishing itself as a trustworthy tool for delineating tumor sizes relative to overall breast volume. This confidence is backed by extensive validation from over 1,600 historical cases across multiple institutions, affirming TumorSight Viz’s readiness for widespread clinical use.

The partnership is not just an alignment of products; it reflects a shared vision of advancing digital healthcare technology on a larger scale. With the combination of SimBioSys's novel software and Ricoh's manufacturing capabilities, both companies aim to accelerate the adoption of these advanced tools in breast cancer treatment.

Looking Ahead

As the collaboration unfolds, healthcare providers are encouraged to reach out through the Ricoh 3D for Healthcare platform for more information or to schedule demonstrations of TumorSight Viz. In a field that continuously seeks innovation, the integration of AI in surgical practices marks a significant step towards improved precision in patient care and outcomes.

This strategic partnership could redefine breast cancer surgery, offering hope and improved treatment options for many patients and bringing technological advancements into everyday clinical workflows.

For more information about SimBioSys and TumorSight Viz, visit SimBioSys's website. To learn about Ricoh 3D for Healthcare and their offerings, check Ricoh's official site.